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Abstract:
Previously epilepsy was recognized as part of the multiple sclerosis (MS) disease spectrum and treat-
ment with antiepileptic drugs was part of symptomatic MS therapy. These comorbidities in the same 
patient despite being well known still has not been fully understood.
The aim of this study was to evaluate incidence and clinical presentation of epilesy in population of 
our MS patients. We included in our study 200 patients evaluated in our MS center, 145 females and 
55 males.
Results: there was no statistically significant difference in mean age, disease duration, EDSS score 
between MS with and MS without epilepsy groups, no differences in clinical presentation of seizures 
according to the previous immunomodulatory treatment (p>0,05). We found EEG abnormalities 
in 50% of patients with MS and seizures, in 35% MS patients without seizures, pooled incidence of 
epilepsy in 3.5% with peak incidence between 4 and 7 years after the onset of multiple sclerosis. There 
was difference of seizure incidence according to clinical course of MS.
The treatment of epilepsy in patients with multiple sclerosis does not requires specific protocols than 
the general epileptic population, but requires individualized approach in order to achieve the best 
treatment for both diseases. 
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Sažetak:
Incidencija epilepsije u bolesnika s multiplom sklerozom
Incidencija epilepsije u bolesnika s multiplom sklerozom Prije je epilepsija bila prepoznata kao dio 
spektra multiple skleroze (MS) kao bolesti, a liječenje antiepileptičkim lijekovima bilo je dio simpto-
matske MS terapije. Interakcije ove dvije bolesti kada se jave u istog pacijenta još uvijek nisu dobro 
istražene , iako su dobro poznate same za sebe.
Cilj ove studije bio je procijeniti učestalost i kliničku prezentaciju epilesije u populaciji naših MS 
bolesnika. U našu smo studiju uključili 200 pacijenata procijenjenih u našem MS centru, 145 žena i 
55 muškaraca.
Rezultati: nije bilo statistički značajne razlike u prosječnoj životnoj dobi, trajanju bolesti, EDSS zbroju 
između MS s i MS bez epilepsijskih skupina, nije bilo razlike u kliničkoj prezentaciji napadaja prema 
prethodnom imunomodulatornom liječenju (p> 0,05). Otkrili smo EEG abnormalnosti u 50% bole-
snika s MS-om i napadajima, u 35% bolesnika s MS-om bez napadaja, ukupnu pojavnost epilepsije u 
3,5% s najvećom učestalošću između 4 i 7 godina nakon početka multiple skleroze. Postojala je razlika 
u učestalosti napadaja prema kliničkom tijeku MS-a.
Liječenje epilepsije u bolesnika s multiplom sklerozom ne zahtijeva posebne protokole od opće 
epileptične populacije, ali zahtijeva individualizirani pristup kako bi se postiglo najbolje liječenje za 
obje bolesti.
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Introduction: 
Multiple sclerosis (MS) is autoimmune disease of the central 
nervous system. Previously epilepsy was recognized as part of 
the MS disease spectrum and treatment with antiepileptic drugs 
was part of symptomatic MS therapy. These comorbidities in the 
same patient despite being well known, still has not been fully 
understood. Seizures appear in only a minority of patients with 
MS, but they can have serious consequences. The treatment of 
MS can be epileptogenic, and antiepileptic treatment can con-
versely worsen the symptoms of MS, therefore further investiga-
tion are needed.1,2 
The risk of epilepsy in patients with multiple sclerosis is 3 to 6 
times higher than the healthy population (general population 
ranges from 0.27 to 1.7%.1, in patients with multiple sclerosis 
(MS) average of 2.3% (range 0.5–10.8%). It is more common in 
young age with peak incidence between 4 and 7 years after the 
onset of multiple sclerosis. It is important to consider that pa-
tients with MS during the course of the disease may show clini-
cal symptoms such as paroxysmal epileptic-like spasms, dizziness, 
diplopia, and more, to differentiate the disease seizure in order to 
establish the correct clinical diagnosis and therapy.3,4
The aim of this study was to evaluate incidence and clinical pres-
entation of epilepsy in population of our MS patients. 
Patients and methods:
We included in our study 200 patients evaluated in our MS 
center, University Department of Neurology, UHC Sestre mi-
losrdnice in Zagreb during last year. MS diagnose was established 
according to revised Mc Donald criteria.5 Diagnose of epilepsy 
was established according to criteria of the International League 
Against Epilepsy (ILAE).6 MS patients were divided in group 
relapse remitted MS (RRMS) and primary progressive MS 
(PPMS) and incidence of epileptic seizures was evaluated in these 
two populations. We evaluated age, gender, disease duration, 
immunomodulatory therapy and EDSS value. For statistical 
evaluation, we used Statistica software (TIBCO Software, Inc. 
Kalifornija, SAD), ANOVA test for demographic data and χ2 test 
for parametric data, statistical significance was p<0,05.
MS PATIENTS WITH EPILEPSY MS PATIENTS WITHOUT EPILEPSY
Females 6 (3%) 139 (69.5%)
Males 1(0.5%) 54 (27%)
Mean age 
(years±standard deviation) 36 ±16
MS disease duration (years) 8 (0-15)
RRMS 5 (2.5%) 155 (77.5%)
PPMS 2 (1%) 38 (19%)
Seizure in relapse of MS 5 (2.5%) 0
Immunomodulatory therapy before 
seizure 3 (1.5%) 0
No Immunomodulatory therapy before 
seizure 4 (2%) 0
EDSS 0-4 160 (80%)
EDSS 4-6 38 (19%)
EDSS >7 2 (1%)
*data were presented as absolute numbers and percentages
Table 1. Patient properties
Original Article
RAD 547. Medical Sciences 54-55 (2021) : 20-23                       www.rad-med.com 22 June 2021   -   Vol 547 = 54-55
Results
We included in our study 200 patients, 145 females and 55 
males, there was no statistically significant difference in mean 
age, disease duration and EDSS score between MS with and 
MS without epilepsy groups (p>0,05), therefore pooled data 
are presented for these parameters. In our study, we found 6 
females and 1 male patient with MS and seizures; while most of 
the patients were seizure free (139 females and 54 males). When 
evaluated seizure incidence according to MS clinical presenta-
tion there was 5 patients with RRMS and 2 patients with PPMS 
(p=0.047); 5 patients had seizures as presentation of MS relapse 
(p=0.048). When evaluating seizure types 3 were generalized sei-
zures and 4 were focal according to ILAE classification, there was 
no differences in clinical presentation of seizures according to the 
clinical course of MS (RRMS; PPMS). There was no difference 
in seizure presentation according to previous immunomodula-
tory therapy (p>0.05). When we correlate EDSS values between 
the groups we did not found statistically significant differences 
between the MS with epilepsy and without epilepsy patients 
(p>0.05). Brain magnetic resonance imaging (MRI) findings 
have shown diffuse lesions, including as well cortical, iuxtacor-
tical lesions and different grades of atrophy but there was no 
statistically significant differences according to the MS popula-
tion without seizures(p>0,05),. We found EEG abnormalities 
in 50% of patients with MS and seizures, in 35% MS patients 
without seizures. 
Discussion
The risk of epilepsy in patients with multiple sclerosis is 3 to 6 
times higher than the healthy population (general population 
ranges from 0.27 to 1.7%.1, in patients with multiple sclerosis 
(MS) average of 2.3% (range 0.5–10.8%). In our study, we 
found pooled incidence of 3.5%, 3% in females and 0.5% in 
males.1,4
It is more common in young age with peak incidence between 4 
and 7 years after the onset of multiple sclerosis, in our study at 
the time of seizure appearance mean duration of the MS was 8 
years. 1,4
It is more prevalent in the female sex, the frequency of seizures 
seems to be related to the number of exacerbations of multiple 
sclerosis and the seat of injury especially when present in the 
cortical or iuxtacorticali (substrate consists of areas of inflamma-
tion and demyelination in the cortex and white matter justacor-
ticale with reactive gliosis, edema and alterations of enzyme ATP 
Na-K dependent). In cases with varying degrees of atrophy it is 
assumed that the alteration of sodium channels may be a com-
mon pathogenetic element in the same patient from the onset of 
epilepsy and multiple sclerosis, especially when epilepsy precedes 
the onset of MS. In our study most of the patients were females, 
most of the seizures appeared in relapse of MS, MRI findings 
have shown diffuse lesions, including as well cortical, iuxtacor-
tical lesions and different grades of atrophy but there was no 
statistically significant differences according to the MS popula-
tion without seizures. 7-9
Seizures are included in the spectrum of multiple sclerosis symp-
toms and they may arise in the course of relapse or always be pre-
sent. Crises can be partial or generalized, primary or secondary, 
with the same prevalence of epileptic general population. Partial 
seizures with or without secondary generalization are the most 
frequent type. Among the partial seizures, focal seizures are twice 
as frequent complex partial unlike the general population in 
which this ratio is reversed. In our study there was no statistically 
significant difference in number of generalized and focal seizures, 
there was no differences in clinical presentation of seizures ac-
cording to the clinical course of MS (RRMS; PPMS).10-12
It is important to consider that patients with MS during the 
course of the disease may show clinical symptoms such as par-
oxysmal epileptic-like spasms, dizziness, diplopia, and more, to 
differentiate the disease seizure in order to establish the correct 
clinical diagnosis and therapy. 11
Seizures can also be a rare side effect of therapies for multiple 
sclerosis in particular glatiramer acetate, fampridine, cannabis 
and derivatives or even more rarely with beta interferon, prob-
ably for a lowering of the seizure threshold. In our study, we did 
not found impact of immunomodulatory or other MS therapy 
on epileptic seizures. 13
EEG abnormalities are present in approximately 60% of patients 
with multiple sclerosis and are generally in relation to the site of 
injury or over the stage of the disease and the particular type of 
course The relationship between the EEG and neuroradiological 
finding to date have not yet been clearly defined. Presumably in 
the early stages of disease flare edema present level of demyelinat-
ing lesions that may have epileptogenic effects would be reduced 
with steroid therapy. Patients with epilepsy and MS have cortical 
inflammatory lesions that would explain focal onset seizures dur-
ing relapses or as debut of MS. However, some patients build up 
numerous epileptogenic processes, developing seizures away from 
relapses, perpetuating neurodegeneration and cognitive impair-
ment. These patients should be the center for new treatment 
strategies targeting the detention of the epileptogenic progres-
sion. We found EEG abnormalities in 50% of patients with MS 
and seizures, but also in 35% of MS patients without seizures, it 
is according to previously mentioned facts.14
Seizure control is essential for people with epilepsy not only 
because of general health, but also because of their psychosocial 
functioning as well as mortality rate reduction, including sudden 
unexpected death (SUDEP).13
The treatment of epileptic disease in patients with multiple 
sclerosis does not requires specific protocols than the general 
epileptic population. We should think only about the comedica-
tion for both disease and possible interactions and side effects, 
for example- use of phenobarbital could accentuate cognitive 
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deficits so it is recommended not to use it. When used, carba-
mazepine, lamotrigine or gabapentin could induce increased 
fatigue, disorders of balance, the cognitive slowing, the onset or 
aggravation of their symptoms of MS such disorders cerebellar, 
pyramidal signs, micturition disorders. The new AEDs are good 
therapeutic option for which the antiepileptic therapy in patients 
with multiple sclerosis. Number of patients in our study was too 
low for statistical evaluation of AED and their impact on disease 
course as well as patient everyday functioning, for these purposes 
further studies should be performed as follow up studies with 
higher number of patients. 13,14
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